20-F: C21 Investments Reports Revenue Growth and Strategic Nevada Expansion Amidst Rising Net Loss and Tax Uncertainties

C21 Investments Inc. reported a 6.5% increase in FY2025 revenues to $30.1 million, driven by the acquisition and opening of a third retail dispensary in South Reno, Nevada, while navigating a higher net loss and significant federal cannabis tax challenges.

Summary

• C21 Investments Inc. reported total revenue of $30.1 million for the fiscal year ended March 31, 2025 (FY2025), a 6.5% increase compared to $28.3 million in the prior full year ended January 31, 2024 (FY2024).
• Gross profit increased to $12.56 million in FY2025 (41.7% gross margin) from $11.15 million in FY2024 (39.4% gross margin), primarily due to economies of scale from cultivation expansion and the addition of a third store.
• Income from operations for FY2025 decreased by 13% to $1.3 million, down from $1.5 million in FY2024, mainly attributed to increased share-based compensation expense and other operational costs.
• The company reported a net loss of $(3.97) million in FY2025, an increase from $(3.31) million in FY2024, largely impacted by a significant income tax expense.
• Adjusted EBITDA for FY2025 was $4.87 million, an increase of $335,336 from $4.53 million in FY2024.
• Free Cash Flow from continuing operations was $4.03 million in FY2025, up from $2.85 million in FY2024.
• C21 Investments acquired and opened a third retail cannabis dispensary in South Reno, Nevada, on June 26, 2024, for a purchase price of $3.5 million.
• The acquisition of the new dispensary was partly funded by a C$4 million private placement of convertible debentures units closed in May 2024.
• The company repurchased and cancelled 2,051,000 common shares in February 2025 for $256,375 and initiated a Normal Course Issuer Bid (NCIB) to repurchase up to 6,002,390 common shares by December 2, 2025.
• All Oregon operations have been classified as discontinued, with the remaining two properties in Oregon sold to third parties in FY2025.
• The company has identified material weaknesses in its internal control over financial reporting, including inadequate segregation of duties and insufficient personnel with appropriate technical accounting knowledge.
• C21 maintains an uncertain tax position of $9.82 million as of March 31, 2025, based on its legal interpretation that Section 280E of the Internal Revenue Code should not apply to its operations.

Sentiment

Score: 5

Explanation: The company shows positive operational growth and strategic execution (new dispensary, share repurchases, improved gross margin, positive Adjusted EBITDA and Free Cash Flow). However, the increasing net loss, significant tax burden due to Section 280E, and ongoing legal disputes introduce substantial financial uncertainty and risk, balancing out the positives.

Positives

• Revenue increased by 6.5% to $30.1 million in FY2025, driven by strategic expansion.
• Gross profit margin improved to 41.7% in FY2025, indicating enhanced operational efficiency and economies of scale.
• Successfully acquired and opened a third retail cannabis dispensary in South Reno, Nevada, expanding the company's retail footprint and increasing cultivation sell-through.
• Achieved positive Adjusted EBITDA of $4.87 million in FY2025, demonstrating strong underlying operational performance.
• Generated positive Free Cash Flow of $4.03 million in FY2025, indicating the ability to generate cash from continuing business operations.
• Repaid the $2.03 million Newman Note in June 2023, reducing debt obligations and increasing financial flexibility.
• Executed a share repurchase and cancellation of 2,051,000 common shares, signaling management's confidence in the company's valuation and commitment to shareholder returns.
• Initiated a Normal Course Issuer Bid (NCIB) to repurchase up to 5% of outstanding common shares, further demonstrating a focus on shareholder value.
• Completed the divestiture of non-core Oregon assets, streamlining operations and focusing resources on the profitable Nevada market.
• Nevada cultivation facility expansion completed in January 2023, more than doubling annual production capacity to 8,100 pounds of high-quality flower.

Negatives

• Net loss increased to $(3.97) million in FY2025 from $(3.31) million in FY2024, primarily due to higher income tax expense.
• Income from operations decreased by 13% to $1.3 million in FY2025, despite revenue growth, impacted by increased share-based compensation and other costs.
• Incurred a significant income tax expense of $4.15 million in FY2025, largely due to the restrictions of Section 280E of the U.S. Internal Revenue Code and associated penalties and interest.
• Maintains a substantial uncertain tax position of $9.82 million related to Section 280E, posing a material potential future liability if challenged by the IRS.
• Identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient personnel with technical accounting knowledge, which could impair accurate financial reporting.
• Wholesale sales declined to $1.4 million in FY2025 from $3.0 million in FY2024, although offset by retail growth.
• Reported a working capital deficiency of $452,928 as of March 31, 2025.
• Ongoing legal proceedings in Oregon and British Columbia continue to consume financial and corporate resources, with unquantified damages alleged in the BC action.

Risks

• Cannabis remains a Schedule I controlled substance under U.S. federal law, subjecting the company to potential regulatory or legal enforcement, litigation, increased costs, and reputational harm, despite state-level legality.
• Proceeds from cannabis operations may be considered proceeds of crime under U.S. federal law, potentially restricting the company's ability to pay dividends or repatriate funds to Canada.
• Difficulty accessing traditional banking services and processing credit card payments due to federal illegality, potentially forcing cash-only operations.
• Operations in the U.S. cannabis market may face heightened scrutiny from Canadian regulators, stock exchanges, and clearing agencies, potentially leading to restrictions on investment or trading.
• Negative shifts in public perception regarding cannabis safety, efficacy, or quality could adversely affect demand for products.
• Evolving and inconsistent state and federal cannabis laws and regulations could impose substantial compliance costs, disrupt business plans, or lead to revocation of licenses.
• Business premises are targets for theft of cannabis products, equipment, and cash, despite implemented security measures.
• Reliance on public and private capital, with no assurance of future funding availability, especially if U.S. federal authorities change their enforcement stance.
• Inherent risk of exposure to product liability claims, regulatory action, and litigation if products cause loss or injury, particularly concerning vape-related illnesses.
• Uncertainty in market development due to the early stage of the state-legal cannabis industry, making forecasts for market size and product sales unreliable.
• Dependence on key inputs and a healthy supply chain, with risks of significant interruption or negative changes in availability or economics.
• Limited operating history makes evaluating the business and prospects difficult, as the company is in an early stage in a rapidly evolving industry.
• No assurance of future profitability given the limited operating history and emerging business sector.
• Strain on management systems and resources due to significant growth, requiring effective implementation of financial controls and expansion of workforce.
• Adverse changes in general economic or political conditions could negatively impact demand and financial performance.
• Significant expenditures required to gain and increase market acceptance of products, with no assurance of success.
• Potential for inadequate or unavailable insurance coverage for risks like business interruption, environmental matters, and product liability.
• High effective U.S. federal income tax rate due to Section 280E of the Code, which prohibits deduction of ordinary business expenses for cannabis businesses; the company's uncertain tax position could lead to significant liabilities if challenged.
• Exposure to significant currency fluctuations between U.S. and Canadian dollars, as revenue is in USD and expenses in both.
• Vulnerability to rising or volatile energy costs due to considerable energy consumption in growing operations.
• Identified material weaknesses in internal control over financial reporting could impair accurate financial reporting or fraud detection.
• Ongoing legal proceedings consume financial and corporate resources and could adversely affect operations and share price.
• Increased competition from small-scale local operators and multi-state operators, as well as illicit market operations.

Future Outlook

The company plans to extend its Nevada retail footprint through value-add acquisitions in existing markets and continue its disciplined approach to growth and financing. It also aims to expand branded CPG through both captive retail and wholesale channels. The broader U.S. cannabis industry is expected to see continued growth, with legal sales projected to reach $44 billion by the end of 2025 and exceed $49 billion by 2026, driven by increasing state legalization and shifting public opinion. The potential rescheduling of cannabis to Schedule III under the Controlled Substances Act could end the effect of Section 280E of the Code on some or all of the Company's operations, which would be a significant positive development, though its timing and certainty remain unclear.

Management Comments

• "We are pleased to announce the purchase for cancellation of over 2 million outstanding Common Shares of C21 as we believe our current market valuation does not reflect the inherent value of our company given our growth trend, and proven track record of generating free cashflow over the last 5 years. Consistent with our strategy, this transaction represents the Company once again taking advantage of an opportunity that we believe will be accretive to our shareholders." Sonny Newman, President and Chief Executive Officer.
• "We continue to strive to be thoughtful stewards of capital and remain focused on pursuing additional accretive growth opportunities." Sonny Newman, President and Chief Executive Officer.
• "With the dispensary's desirable location in a high traffic, flourishing area of South Reno, we anticipate strong revenue growth from this acquisition, along with the added benefit of allowing us to expand the portion of our cultivation capacity sold through our retail channel." Sonny Newman, President and Chief Executive Officer.

Industry Context

The U.S. cannabis industry is rapidly emerging, with 80% of U.S. states having legalized cannabis for medical or adult-use. Public support for legalization is high (88% for medical/recreational use). Despite state-level legality, cannabis remains a Schedule I controlled substance under federal law, creating significant regulatory and banking challenges (e.g., Section 280E, limited banking access). Legislative efforts like the SAFE Banking Act and MORE Act have faced hurdles but continue to be reintroduced. The potential rescheduling of cannabis to Schedule III is a significant ongoing development that could alleviate tax burdens. The industry is experiencing consolidation and increased participation from multi-state operators, leading to heightened competition.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct benchmarking against industry standards.
• C21 Investments' strategic focus on vertical integration in limited-license states like Nevada aligns with a common and often successful approach among cannabis operators aiming to control the supply chain and maximize margins.
• The reported gross margin of 41.7% and positive Adjusted EBITDA and Free Cash Flow suggest a relatively healthy operational performance, especially considering the significant tax burden imposed by Section 280E on U.S. cannabis businesses, which often leads to lower profitability for peers.
• The company's ability to generate positive cash flow from operations and execute share repurchases indicates a level of financial discipline and operational efficiency that may differentiate it from less mature or less well-managed peers in the fragmented U.S. cannabis market.

Corporate Governance

Legal Proceedings

• **Oregon Action**: A complaint was filed in April 2019 alleging contract, employment, and statutory claims for $612,500 in damages. While the Company was largely dismissed, the Court of Appeals reversed prior judgments, remanding the case against Phantom Brands, LLC, Swell Companies Limited, and two former employees. The Company was awarded $107,622.50 in attorney's fees and $1,252 in costs in September 2024, which is currently under appeal by the plaintiffs. Collection efforts are ongoing.
• **British Columbia Action**: Proudest Monkey Holdings, LLC sued the Company in October 2019 to compel the issuance of shares related to the EFF purchase. The Company counterclaimed for breach of contract, repudiation, indemnity, and fraudulent/negligent misrepresentation, alleging $2,774,177 in damages. This action remains in the discovery stage, with a trial scheduled for three weeks in September 2025.

Related Party Transactions

• Lease liabilities due to a company controlled by the Chief Executive Officer (CEO) totaled $4,630,273 as of March 31, 2025.
• Amounts paid to the CEO or companies controlled by the CEO for leases were $768,143 for the year ended March 31, 2025.
• Amounts paid to the CEO or companies controlled by the CEO for remuneration were $200,000 for the year ended March 31, 2025.
• Consulting fees paid to a director (Todd Harrison, principal of CB1 Capital Advisors) amounted to $60,000 for the year ended March 31, 2025. The consulting agreement with CB1 Capital Advisors terminated on September 30, 2024, but CB1 continues to invoice $5,000 per month, cancelable at any time.
• Salary paid to directors and officers totaled $489,042 for the year ended March 31, 2025.
• Share-based compensation to directors and officers amounted to $513,735 for the year ended March 31, 2025.
• The promissory note owing to the President and CEO, Sonny Newman (Newman Note), was fully repaid on June 1, 2023.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity financings but may benefit from ongoing share repurchase programs and strategic growth initiatives. Subject to market volatility and inherent risks of the cannabis industry.
• **Employees**: Benefit from continued employment and growth opportunities within the expanding Nevada operations. Non-U.S. citizen employees face the risk of being barred from U.S. entry due to federal cannabis laws.
• **Customers**: Gain expanded retail access with the opening of the new South Reno dispensary and continued access to a wide variety of cannabis products.
• **Suppliers**: Maintain business relationships, but may be impacted by global supply chain issues affecting key inputs.
• **Creditors**: Debt obligations are being serviced, but the company's working capital deficiency and significant uncertain tax position could pose challenges to meeting all financial commitments.
• **Regulatory Bodies**: The company continues to engage with and comply with state-level regulations, but remains exposed to potential federal enforcement actions due to the conflict between state and federal cannabis laws.

Next Steps

• Integration and rebranding of the new South Reno dispensary under the Silver State Relief banner.
• Continued disciplined approach to growth and financing.
• Internal production of product to expand Nevada retail footprint.
• Remediation of material weaknesses in internal control over financial reporting by retaining additional in-house accounting personnel, enhancing direct management oversight of complex transactions, and expanding services with independent accounting consultants.
• Refiling of amended U.S. federal income tax returns for years ended January 31, 2022, 2023, 2024, and March 31, 2024, based on legal interpretations challenging tax liability under Section 280E.
• Ongoing collection efforts through garnishment procedures in the Oregon Action.
• Trial date scheduled for three weeks in September 2025 for the British Columbia Action.
• Monitoring of U.S. federal law and the law in all jurisdictions regarding cannabis.
• Potential future expansion into other U.S. states that have legalized cannabis use.
• Potential establishment of a program to hedge foreign currency exposure.
• Continued monitoring of cybersecurity risks and enhancement of protective measures.
• Consideration of increased Board oversight for cybersecurity as the company's situation evolves.

Key Dates

Recommendation

Keywords

Cannabis, Nevada, Retail Dispensary, Cultivation, SEC Filing, Form 20-F, Financial Results, Adjusted EBITDA, Free Cash Flow, Share Repurchase, Convertible Debentures, Section 280E, Regulatory Risk, Cannabis Industry, Vertical Integration, OTC Markets, CSE, Silver State Relief, Deep Roots Harvest, Corporate Governance, Internal Controls, Legal Proceedings, Supply Chain, Taxation